Eton Pharmaceuticals Relaunches HEMANGEOL With Exclusive Anovo Distribution and $0 Co-pay
Eton Pharmaceuticals has relaunched HEMANGEOL as an oral propranolol solution exclusively through Anovo Specialty Pharmacy, integrating its Eton Cares patient support program offering $0 co-pay and expanded assistance. HEMANGEOL, the only FDA-approved treatment for infantile hemangiomas, treats 5,000–10,000 U.S. infants annually during a critical five-week to five-month window.
1. Relaunch Details
Eton Pharmaceuticals has relaunched HEMANGEOL® (propranolol) Oral Solution exclusively through Anovo Specialty Pharmacy, integrating its Eton Cares program to provide $0 co-pay for eligible commercially insured patients and expanded patient assistance. This specialty pharmacy model streamlines access, prescription management, and therapy initiation for caregivers and healthcare providers.
2. Market Opportunity
HEMANGEOL is the only FDA-approved systemic therapy for proliferating infantile hemangioma, a rare pediatric condition affecting 5,000 to 10,000 infants in the U.S. each year. Treatment is typically initiated between five weeks and five months of age and continues for approximately six months, representing a narrow window for optimal outcomes.
3. Strategic Implications
By combining exclusive specialty distribution with comprehensive patient support, Eton aims to remove access barriers, accelerate market uptake and improve revenue visibility. This targeted launch enhances Eton’s rare disease portfolio and could drive sustained growth in its pediatric dermatology segment.